Loading clinical trials...

COMPLETEDPHASE2

Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma)

Phase II Study on the Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy

NCT02842723•Institut Curie

View on ClinicalTrials.gov

Summary

Prospective, open labelled, phase II, monocenter trial to combine partial surgery resection and protontherapy to management paediatric craniopharyngioma.

Detailed Description

This study is phase II prospective, open labelled, phase ii, monocenter. The main objective is to evaluate the fractionated high precision radiotherapy with a dose of 59,5 Gy (1,7 Gy daily, 5 fractions per week).

Eligibility

Age

3 - 16 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically documented craniopharyngioma
•Age range between 3 and 16 years
•Landsky performance status \> 60
•Incomplete surgical resection or simple biopsy
•Solid and/or cystic aspect on imaging
•Irradiation performed at the time of presentation or of local progression
•Signed informed consent by parents or by legal representative (with copy to each participating center)

Exclusion Criteria

•Previous history of radiotherapy (including stereotactic) administered to the head and neck region
•Severe vasculopathy
•Participation to a concurrent study
•Contra-indication to general anesthesia in children below 5 years
•Patient non-compliant to a minimum 30 mn immobilisation
•Patient deprived of freedom or under guardianship
•Patient not expected to be followed in a long run

Locations (3)

Institut Curie

Paris, France

Groupe Hospitalier Necker Enfants Malades

Paris, France

Gustave Roussy

Villejuif, France

Key Dates

Start Date

March 1, 2010

Primary Completion Date

November 13, 2018

Completion Date

February 2, 2021

Last Updated

January 31, 2024

Enrollment

ACTUAL participants

Conditions

Craniopharyngioma

Interventions

Protontherapy

RADIATION

ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

NCT05233397

Adamantinomatous CraniopharyngiomaRecurrent Adamantinomatous Craniopharyngioma

View study

RECRUITINGPHASE1/PHASE2

Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

NCT06970145

Craniopharyngiomas

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 31, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma)

Inclusion Criteria

Exclusion Criteria

ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

Craniopharyngioma and Pregnancies

Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery

The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors